GC304 Adeno-Associated Virus

Main purpose: To evaluate the safety and tolerability of GC304 adeno-associated virus injection in the treatment of primary hypertriglyceridemia patients with a history of acute pancreatitis after 12 weeks of medication Secondary objectives: 1. To evaluate the changes in triglyceride levels within 12 weeks after the administration of GC304 adeno-associated virus injection; 2. To evaluate the immunogenicity response within 12 weeks after the administration of GC304 adeno-associated virus injection; 3. To evaluate the pharmacokinetics (whole blood GC304 vector genome copy number) of GC304 adeno-associated virus injection within 12 weeks after the administration of GC304 adeno-associated virus injection; 4. To evaluate the shedding of viral vector within 12 weeks after the administration of GC304 adeno-associated virus injection.